Evidence map›Paper›PMID 26021196›Full record

ReviewGastroenterology clinics of North America2015

Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

Matthew J Whitson, Gary W Falk

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Opportunities to Avoid Invasive Cancer by Diagnosis and Interception of Preneoplastic Lesions and Cancer Risk Conditions.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Review
  4. Article
  5. Predictors of Progression in Barrett's Esophagus.Current treatment options in gastroenterology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew J WhitsonDivision of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, 7th floor, South Pavillion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
Gary W FalkDivision of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, 7th floor, South Pavillion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: gary.falk@uphs.upenn.edu.

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
Transformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NAKAGAWA, HIROSHI · 2003 to 2023
$31.7M
Weight loss-induced Microbiome and Adipokine Changes in Barrett's EsophagusU54CA163004 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN, RUSTGI, ANIL K · 2011 to 2022
$12.5M
NCI NIH HHS P01 CA098101NCI NIH HHS P01-CA098101NCI NIH HHS U54 CA163004NCI NIH HHS U54-CA163004NIDDK NIH HHS P30 DK050306NIDDK NIH HHS P30-DK050306
6 · The paper itself

Abstract

The prevalence of esophageal adenocarcinoma is increasing dramatically. Barrett's esophagus remains the most well-established risk factor for the development of esophageal adenocarcinoma. There are multiple clinical, endoscopic, and pathologic factors that increase the risk of neoplastic progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett's esophagus. This article reviews both risk and protective factors for neoplastic progression in patients with Barrett's esophagus.

Indexed as

AdenocarcinomaBarrett EsophagusBiomarkers, TumorDisease ProgressionEsophageal NeoplasmsEsophagoscopyEsophagusHumansMetaplasiaPrecancerous ConditionsProtective FactorsRisk FactorsBiomarkers, TumorBarrett’s esophagusDysplasiaEsophageal adenocarcinomaNeoplastic progressionRisk factors

Identifiers

PMID26021196
PMCPMC4449455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.